drugset
drugset / Trial / NCT06631170

Efficacy and Safety of Roflumilast Cream in Subjects With Atopic Dermatitis

NCT06631170 ↗

Phase 3 Completed 354 enrolled Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will assess the safety and efficacy of Roflumilast cream versus vehicle applied once a day for 4 weeks by subjects with atopic dermatitis.

Timeline

Start
2024-11-21
Primary completion
2025-05-27
Completion
2025-07-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Roflumilast Small molecule 0.15 % Topical

Indications

atopic eczema